Clinical AdvancementsUniQure delivered a clean and focused update, with regulatory, manufacturing, and clinical progress keeping AMT-130 on track for a Biologics License Application filing and potential approval.
Regulatory ProgressFDA alignment and CMC progress keep AMT-130 on track for accelerated approval.
Therapy DevelopmentAMT-130 is well-positioned as the first potential disease-modifying treatment for Huntington's disease.